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The utility of induced pluripotent stem cells (iPSCs)
as models to study diseases and as sources for cell
therapy depends on the integrity of their genomes.
Despite recent publications of DNA sequence varia-
tions in the iPSCs, the true scope of such changes
for the entire genome is not clear. Here we report
the whole-genome sequencing of three human
iPSC lines derived from two cell types of an adult
donor by episomal vectors. The vector sequence
was undetectable in the deeply sequenced iPSC
lines. We identified 1,058–1,808 heterozygous sin-
gle-nucleotide variants (SNVs), but no copy-number
variants, in each iPSC line. Six to twelve of these
SNVs were within coding regions in each iPSC line,
but 50% of them are synonymous changes and
the remaining are not selectively enriched for known
genes associated with cancers. Our data thus
suggest that episome-mediated reprogramming is
not inherently mutagenic during integration-free
iPSC induction.
INTRODUCTION
The iPSC technology holds great promise for human stem cell
biology and regenerative medicine, but the reprogramming
processes and the resulting iPSCs remain incompletely charac-
terized. Specifically, it is not clear how many changes occur at
the DNA level during reprogramming. With recently available
technologies such as single-nucleotide polymorphism (SNP)
array and exome sequencing, several recent studies reported
first glimpses of genetic abnormalities in human iPSCs derived
from fibroblasts (Gore et al., 2011; Hussein et al., 2011; Laurent
et al., 2011; Martins-Taylor et al., 2011; Mayshar et al., 2010).
Nucleotide substitutions, copy-number variation (CNV) changes,Cand other chromosomal aberrations, which are either pre-exist-
ing or generated during reprogramming, may be selected for
iPSC induction and/or expansion (Pera, 2011). In addition, the
origin of starting cell types may influence the quality of derived
iPSCs (Kim et al., 2010; Polo et al., 2010). A whole-genome
sequencing (WGS) analysis is necessary to assess potential
alterations in the entire nuclear and mitochondrial genomes,
because recent WGS studies confirmed the notion that DNA
mutational rates in somatic cells are lower in exons than in un-
transcribed regions probably because of transcription-coupled
DNA repair (Lee et al., 2010; Pleasance et al., 2010). In this study,
we conductedWGSanalysis to determine the DNA sequences of
three human iPSC lines.RESULTS
Generation of Multiple iPSC Lines from Different
Tissues of the Same Adult Donor
The iPSC lines were derived with plasmid vectors based on the
EBNA1/OriP episomal replicon, from two cell types of a healthy
donor (a 31-year-old anonymous male of mixed ethnic back-
grounds). The relationship of the four iPSC lines and their
somatic cell ancestors are shown in Figure 1. Bone marrow
CD34+ cells were used to generate the BC1 iPSC line after
4 day culture with a single episomal vector (pEB-C5) expressing
five reprogramming genes (Chou et al., 2011). The second iPSC
line BCT1 was derived from the same cultured CD34+ cells by
using an additional episomal vector expressing SV40 large T
antigen (SV40-LT) gene together with pEB-C5. The CD34
marrow mononuclear cells were used to establish adherent
marrow stromal cells (MSCs) (Cheng et al., 2003). The estab-
lished MSCs after primary and first passage (p1) in culture
(15 days total) were then used to generate two iPSC lines, E1
and E2 (see Experimental Procedures). By using standard
methods for characterization of expanded iPSC lines such as
BC1 (Chou et al., 2011), we confirmed normal pluripotency and
karyotyping (by G-banding) of iPSC lines E1 (Figure S1 available
online), E2 (data not shown), and BCT1 (Figure S3). For theell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc. 337
Bone marrow mononuclear cells from a
healthy adult male donor (BM 2426)
BC1 iPSC
(p25)
CD34+
CD34-
MSC p1
E1 iPSC
(p15)
E2 iPSC
(P15)
BCT1iPSC
(p18)
CD34+
(Adherent) 
After 15 days in culture 
After 4 days in culture 
S2 
S1 
S5 
S6 
S3 
S4 
p51 Neural
cells
Figure 1. Relationship of iPSC Lines and Their Parental Somatic
Cells Used in This Study
Mononuclear cells from bone marrow (BM) of healthy adult donor (BM 2426)
were separated into CD34+ cells (1%) and CD34-depleted (CD34) cells.
The CD34+ cells were cultured for 4 days with hematopoietic cytokines before
being reprogrammed by episomal vectors (left). The BC1 iPSC line was
derived by using a single plasmid pEB-C5 whereas the BCT1 iPSC line was
derived by addition of a second plasmid pEB-Tg. The BM CD34 cells were
used to establish cultures of marrow stromal cells (also called mesenchymal
stem cells or MSCs) by first selecting adherent cells followed by selective
expansion of MSCs for an additional 13 days (after primary and first passage).
The harvested MSCs after first passage (p1) were used for reprogramming
similarly by episomal vectors. Two independent iPSC lines, E1 and E2, were
established and expanded for 15 passages (p15). Functional characterizations
of E1 and BCT1 iPSC lines are shown in Figures S1 and S2, and character-
ization of BC1 iPSC line was published previously (Chou et al., 2011). Three
expanded and characterized iPSC lines, BC1, BCT1, and E1 (boxed), were
also analyzed by whole-genome sequencing at deep coverages. This was
done in pair with the parental somatic cells (also boxed). Although S1/S2
samples were sequenced at BGI as one pair, S3/S4 and S5/S6 samples were
sequenced at NIH as two pairs.
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expanded iPSC lineswere cultured under a feeder-free condition
(on Matrigel) for at least one passage to reduce mouse feeder
cells before total DNA was extracted. In addition, DNA was ex-
tracted by the same method from the corresponding parental
cells, i.e., the cultured CD34+ cells and the p1 MSCs. DNA
from these somatic samples and from iPSCs at various
passages were also used for other analyses.
Deep and Pair-wise Whole-Genome Sequencing of
Three iPSC Lines and Their Parental Somatic Cells
To reduce false positive errors of differences in shotgun DNA
sequencing resulting from variations such as library preparations
and sequencing procedures (Ajay et al., 2011; Kinde et al., 2011),
we sequenced the iPSC lines (BC1, BCT1, and E1) with their
parental somatic cells at the same time in a pair-wise fashion
by Illumina HiSeq2000 technology. For all three pairs, >1.5 3
109 reads per sample were generated and analyzed. Table 1
shows a summary of sequence analyses of the three iPSC lines.338 Cell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc.Weobtained alignable DNA sequences of >130Gb for each iPSC
line and their parental cells. The amount of sequence data is
equivalent to 483 or higher coverage of the haploid (nuclear)
genome. Sequence analysis indicated that we achieved high-
quality coverage (i.e., sufficient coverage in all six samples to
call genotypes with >99.8% accuracy) for >94% of the auto-
somal genome of each sample. This level of deep and pair-
wise sequencing of six related genomes (from the same person)
provides us a high level of confidence to detect true and small
sequence differences.
Absence of Episomal Vector Sequence in the Genomes
of the iPSC Lines
The deep sequencing of the total DNA (5 mg or from 800,000
iPSCs) provides more definitive evidence for the lack of vector
DNA (either integrated or as episome) in these iPSC lines. We
did not detect the pCEP4 vector backbone sequence above
background in any of the three sequenced iPSC lines derived
by episomal vectors. This conclusion was further supported by
the PCR method that would detect 0.2 copies of vector DNA
per cell (or a total of 300 copies per the cell population tested)
as shown in Figures S1 and S2 and in previous studies (Chou
et al., 2011).
Single-Nucleotide Variations in the Genomes
of the iPSC Lines
When compared to the human reference genome sequence
(hg19), we identified approximately 4.2 million single-nucleotide
variants (SNVs) in each of the iPSC lines as well as in their
parental CD34+ cells and MSCs (Table 1). Some of these SNVs
were aligned to repetitive regions of the reference genome (in
parentheses). This level of sequence variations is comparable
to those of other sequenced human genomes (Bentley et al.,
2008; Ding et al., 2010; Lee et al., 2010; Pleasance et al., 2010;
Ajay et al., 2011). When the sequences between each iPSC
line and its parental cells were directly compared, 1,058 to
1,808 likely SNVs were identified between each iPSC line and
its parental somatic cells sequenced in pairs (Table 1). All
SNVs found in iPSCs were heterozygous (i.e., single-allele)
changes as compared to their parental somatic cells. Impor-
tantly, none of these iPSC-associated SNVs are shared among
the three iPSC lines. Neither did we observe any clustering of
these variations in specific chromosomal regions.
SNVs in Known Functional Elements of the Genome
To investigate functional relevance of SNVs found in iPSCs after
induction and expansion, we next focused on SNVs in exons,
especially those not present in dbSNP (build 132) database as
reported previously. High-quality sequencing revealed six
SNVs in BC1 iPSCs residing within the coding regions of six
different genes (Tables 1 and 2). Three of them are nonsynony-
mous (Table 2). The paired sequencing data revealed six SNVs
in coding regions of six different genes in BCT1 iPSCs (derived
from the same CD34+ cells); two of them are nonsynonymous
(Tables 1 and 2). Twelve SNVs in E1 iPSCs were found in the
coding regions of 12 different genes; 6 of them are nonsynony-
mous and one is a truncation (Tables 1 and 2). In searching for
small insertions or deletions (indels) in the coding sequences
that are unique to the three iPSC lines, we identified and
Table 1. Summary of Sequencing Three Pairs of iPSC Lines and Their Parental Somatic Cells
Features/iPSC Lines BC1 BCT1 E1
Total nucleotides sequenced 172 Gb 153 Gb 217 Gb
Alignable nucleotides 165 Gb 142 Gb 134 Gb
Genome coverage (fold) 593 513 483
Total SNVs (compared to the hg19 reference) 4,158,672 (2,193,600)a 4,207,199 (2,237,532) 4,231,439 (2,259,512)
Total SNVs (compared to parental cells) 3,234 (2,217) 4,850 (3,458) 4,470 (3,053)
High-quality, filtered SNVs 1,058 (626) 1,109 (662) 1,808 (1,029)
SNVs in intergenic regions 676 (420) 684 (438) 1,125 (678)
SNVs in conserved noncoding regions 376 (201) 420 (225) 674 (352)
SNVs in introns 367 (206) 409 (229) 664 (360)
SNVs in 50 or 30 UTRs 11 (4) 13 (1) 20 (3)
SNVs in coding regions 6 6 12
Synonymous (S) 3 4 5
Nonsynonymous (NS) 3 2 6
Nonsense 0 0 1
NS:S ratio 1 0.5 1.4
Coding region indels 0 0 2
SNVs in CpG islands 2 0 7
SNVs in sno/microRNA regions 0 1 0
SNV in mitochondrial genome 1 (nt 89) 0 0
Vector sequences anywhere none none none
BC1 and BCT1 iPSC lines were derived from the same batch of CD34+ cells cultured for 4 days. E1 iPSC line were derived fromMSCs established from
CD34 (adherent) cells after culture of 15 days. Parental cultured CD34+ cells (twice) andMSCswere sequenced at similar depths in each pair together
with an iPSC line. BC1 iPSC/CD34+ pair (S1/S2) was sequenced at BGI, and the E1 iPSC/MSC (S3/S4) and BCT1 iPSC/CD34+ (S6/S5) pairs were
sequenced at NIH.
a SNVs: single-nucleotide variations. The SNV counts in parentheses are those that lie within regions annotated in the UCSC hg19 ‘‘RepeatMasker’’
track.
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iPSCs (Table 2).
In addition, there were single-nucleotide variations in the 50 or
30 untranslated regions (UTRs), introns, and noncoding regions
deemed ‘‘conserved’’ by the program PhyloP when run on
UCSC’s 46-way multialignments (Table 1). All of these changes
could potentially affect gene expression. Of the 1,058 SNVs
between BC1 iPSCs and CD34+ cells, only 2 lie in a CpG island
near a promoter, and none lie within the sno/microRNA regions in
the UCSC’s sno/microRNA track. For BCT1 iPSCs, there were
no SNVs in the CpG islands but one in the micro RNA mir-124-
2. For other changes in the E1 iPSC line, seven of them are within
CpG islands and none in the sno/microRNA regions (Table 1).
Validation of SNVs by Genomic PCR and Sanger DNA
Sequencing
We set to confirm the presence of SNVs and indels located in the
exons and selected ones in the introns or UTRs of the iPSC
genomes by using genomic PCR (with specific primers shown
in Table S2) followed by Sanger sequencing. We confirmed 48
out of total 51 SNVs tested (Table S1), for an overall confirmation
rate of 94%. Two of the putative nucleotide substitutions (one in
BC1 and the other in E1 iPSCs) and a single-nucleotide deletion
in the ZNF479 gene in E1 iPSCs could not be confirmed by this
approach, and therefore are likely to have been false positive
calls. Alternatively, the unchanged alleles may have been prefer-Centially amplified during PCR reactions, leading to confirmation
failure. Thus, the vast majority of sequence changes at non-
repetitive regions that are identified by deep WGS via the
HiSeq2000 technology, along with appropriate filtering, are real.
Additionally, we analyzed discordance of two somatic cell
types that were both sequenced together: CD34+ cells as
sample S5 and MSCs as sample S3 from the same donor (Fig-
ure 1). We found 283 possible SNVs between the two cultured
somatic cell types, most of them in repetitive regions (data not
shown). The subsequent PCR and Sanger sequencing failed to
confirm any of the ten randomly selected putative SNVs in non-
repetitive regions; therefore, they are probably false positives.
Our WGS analyses corroborate with recent findings of the noise
levels even by the HiSeq2000 technology, albeit very small
(Ajay et al., 2011; Kinde et al., 2011). These data also highlight
the importance of validating potential SNVs revealed by WGS
analysis. In addition, our data suggest that the cell cultures of
CD34+ cells and MSCs for 4–15 days did not introduce somatic
mutations significantly.
Analysis of SNVs in Different Passages of the Same iPSC
Line or between Different iPSC Lines Derived from the
Same Somatic Cell Population
The sequence variants were stably maintained in the BC1 iPSC
line, because we detected the same variants at an earlier
passage (p11) and a later passage (p51) as in the sequencedell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc. 339
Table 2. Sequence Variants in the Coding Regions in BC1 and E1 iPSCs
iPSC Lines Gene Name Chromosome Position Ref Allele Variant Allele Variant Type
BC1 CNBD1 8 88365930 G A nonsynonymous
ITGA11 15 68650878 T C nonsynonymous
SLIT2 4 20490512 C T nonsynonymous
DHX34 19 47865827 C T synonymous
DOCK1 10 128836023 C T synonymous
PRPS1L1 7 18066668 A G synonymous
BCT1 ADAMTS17 15 100657067 C T nonsynonymous
TG 8 133961089 C T nonsynonymous
CDH4 20 60318830 G A synonymous
EPPK1 8 144941146 G C synonymous
MCM10 10 13213236 C A synonymous
OR8K1 11 56113928 C T synonymous
E1 SDHA 5 231082 C T stop
DHX33 17 5359463 C A nonsynonymous
FAM3B 21 42717750 T A nonsynonymous
KCNH8 3 19389396 C A nonsynonymous
HRH1 3 11301698 C G nonsynonymous
IRF4 6 397216 C T nonsynonymous
ZNF226 19 44677036 G C nonsynonymous
CYP11B2 8 143999035 C T synonymous
HIST3H2A 1 228645201 A G synonymous
HJURP 2 234746286 C T synonymous
PRKD2 19 47197220 G A synonymous
RPL13AP6 10 112696395 G A synonymous
SETD8 12 123892105 CCAAA – del CCAAA
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differentiated from BC1 iPSCs (Table S1). Importantly, none of
the confirmed 16 variants tested were detected in the parental
CD34+ cells or in the sibling BCT1 iPSC line (at least at the level
of <0.1%). Similar results were obtained with MSC-derived
iPSCs: none of the confirmed 25 variants found in E1 iPSCs
were detected in a sibling iPSC line E2 or in their common
parental MSCs used for reprogramming (Table S1). In addition,
the six heterozygous variants found in BCT1 iPSCswere not pre-
sented in the sibling BC1 iPSC line. Therefore, none of the SNVs
found by WGS and further confirmed by Sanger sequencing are
shared among the three iPSC lines.
Analysis of the Mitochondrial Genome
We also obtained high-quality and deep coverage of the mito-
chondrial genomes. No iPSC-specific substitutions were found
in the BCT1 and E1 iPSCs. In the BC1 iPSC line, however, there
is a single substitution at nt89 (T>C) in the 50 highly variable, non-
coding region of the mitochondrial genome (16.5 kb). This nucle-
otide substitution was present in all the sequencing reads of the
BC1 iPSCs (see Discussion below).
Absence of CNV Alterations in the iPSC Lines
The WGS with deep-depth and paired-end read mapping data
also provides us a new way to assess CNVs changes after re-
programming as compared to parental somatic cells. We used340 Cell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc.three prediction programs for CNV detection: RDXplorer (Yoon
et al., 2009), CNVseq (Xie and Tammi, 2009), and BreakDancer
(Chen et al., 2009) on the three pairs of DNA samples (iPSCs
versus respective parental somatic cells) from the same person.
No tenable examples of CNV differences between an iPSC line
and pair-wise sequenced parental cells were found by more
than one of the three methods.
To validate the absence of new CNVs in the integration-free
iPSC lines derived by episomal vectors, we also used Human-
Omni2.5-Quad BeadChips that measure 2.5 million SNP
markers to detect CNVs and other structural changes in iPSC
lines BC1 and E1, as compared to their corresponding parental
somatic cells from the same person. For BC1 iPSCs, we
analyzed the iPSCs at three different passages: 11, 28, and 51,
together with the parental CD34+ cells. For E1 iPSCs, p17 was
used together with its parental MSCs. The call rates of SNP
alleles for all the DNA samples were >99%, and the data met
the desired quality control requirements (data not shown).
Potential CNVs were detected with cnvPartition, PennCNV
(Wang et al., 2007), and Nexus and summarized in Table S3.
With the 2.5M SNP array, we were able to detect CNVs in the
range of few kilobases in length. The two smallest CNVs
(2.02 kb and 2.75 kb) are shown in Figure S3, which are shared
by all six samples of iPSCs and parental somatic cells. The over-
all numbers of CNVs in the iPSCs and their parental cells are
similar to other human somatic cells, because the numbers of
Table 3. Genuine CNVs Detected in the iPSCs and Parental
Somatic Cells
Chr
Copy
Number Start End Length
Method of
Detection
1 0 8105122 8114476 9354 PennCNV,
CNVPartition,
Nexus
1 1 190093507 190134936 41429 PennCNV,
CNVPartition,
Nexus
1 1 195089923 195146893 56970 PennCNV,
CNVPartition,
Nexus
2 3 95884787 95890722 5935 CNVPartition
3 3 77913197 77920280 7083 PennCNV,
CNVPartition
3 1 113584277 113599333 15056 PennCNV,
CNVPartition
4 1 11983684 11993214 9530 PennCNV,
CNVPartition
5 0 33143879 33149247 5368 CNVPartition
6 1 79020533 79092458 71925 CNVPartition
6 1 93631870 93635080 3210 CNVPartition
6 1 113012462 113023906 11444 CNVPartition
7 1 49144752 49150490 5738 CNVPartition
7 1 139841470 139847922 6452 CNVPartition
7 1 145424894 145427315 2421 CNVPartition
7 1
(deletion)a
66762793 66803212 40419 CNVPartition,
Nexus
7 3 151512420 151745955 233536 Nexus
7 0 20717299 20720053 2754 PennCNV,
CNVPartition,
Nexus
8 1 63378480 63385988 7508 CNVPartition
8 1 39351738 39499553 147815 PennCNV,
CNVPartition
9 1 580454 598622 18168 PennCNV,
CNVPartition
9 1 4491352 4494129 2777 PennCNV,
CNVPartition
10 1 91988554 91991990 3436 CNVPartition
10 1 26725084 26730905 5821 PennCNV,
CNVPartition
10 3 46561933 47173875 611942 PennCNV,
CNVPartition,
Nexus
11 0 102254658 102261874 7216 CNVPartition
12 1 12424251 12433136 8885 CNVPartition
12 1 121202830 121215756 12926 CNVPartition
12 0 128624494 128628185 3691 CNVPartition
12 1 103185002 103193085 8084 Nexus
12 3 34211024 34744278 533254 PennCNV,
CNVPartition,
Nexus
13 3 62488915 62512304 23389 CNVPartition,
Nexus
Table 3. Continued
Chr
Copy
Number Start End Length
Method of
Detection
13 0 31430761 31435768 5007 PennCNV,
CNVPartition,
Nexus
13 1 36968549 37018275 49726 PennCNV,
CNVPartition,
Nexus
15 1 22615864 22635687 19823 CNVPartition
15 1 79809091 79958158 149067 PennCNV,
CNVPartition,
Nexus
15 1 22010825 22104326 93,502 PennCNV,
Nexus
16 0 163625 165653 2028 CNVPartition,
Nexus
16 1 20421133 20440897 19764 PennCNV,
CNVPartition
16 1 33849764 33929519 79755 PennCNV,
CNVPartition
16 3 44973739 45446855 473116 PennCNV,
CNVPartition,
Nexus
17 1 76309874 76312824 2950 CNVPartition
17 1 46346285 46353510 7225 PennCNV,
CNVPartition
19 1 23974942 23977215 2273 CNVPartition
19 3 21623408 21639452 16,045 PennCNV
20 0 55019459 55021582 2124 Nexus
aAsterisk denotes a deletion found only in BC1 p51 (also see Figure S4).
All others were shared in all six samples.
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CCNVs predicted in these cells are comparable with the median
value for a larger cohort of 84 unrelated human samples
analyzed by PennCNV with the same parameters (Table S3).
The potential CNVs were further evaluated by visual examina-
tion with both GenomeStudio and Nexus, and only 45 of them
were deemed to be real (Table 3). Importantly, all of these 45
CNVs are shared among all 6 tested samples (both iPSCs and
parental cells), except for one that is unique to BC1p51 iPSCs.
After detailed analyses, this putative CNV was found to be an
incomplete deletion in a region (40.42 kb) containing many
segmental duplications within chromosome 7q11.21. Visual
demonstrations of the incomplete deletion are shown in Fig-
ure S4. The putative CNV or alteration was found only in the
51st passage of the BC1 iPSCs (not sequenced) but not in other
five samples including BC1 iPSCs of earlier passages (p11 and
p28; p25 was sequenced). The exact nature of the incomplete
deletion in this region remains to be determined. It is also well
known that extensively cultured human ESCs and iPSCs often
contain CNV alterations, although not at this locus (Laurent
et al., 2011; Martins-Taylor et al., 2011). Therefore, our SNP anal-
ysis effectively validated theWGS data: as compared to parental
cells, essentially no new CNVs were introduced to the episome-
mediated, integration-free iPSC lines.ell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc. 341
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We report here results of WGS analyses of three iPSC lines and
their parental somatic cells that were reprogrammed by
episomal vectors. We confirmed that the episomal vector DNA
did not integrate in the genome or persist in the three character-
ized iPSC lines, nor did it alter the structures of the iPSC
genomes at detectable levels. The three fully sequenced iPSC
lines derived from two different cell types of the same person
would provide valuable references or standards with DNA
sequence information, for future studies of genomic integrity
and epigenomics (such as DNA methylation) of iPSCs before
and after differentiation.
The present study corroborates with a recent report that
6 SNVs or small sequence changes were found in exonic
regions of examined iPSC lines derived from fibroblasts by
various reprogramming methods (Gore et al., 2011). However,
our deep DNA sequencing of the whole genome also allowed
us to detect SNVs and other sequence changes in nonexonic
regions (>98%) of the nuclear genome and in the mitochondrial
genome. We found 1,058–1,808 sequence changes, mostly
SNVs, per genome in the three iPSCs after induction and expan-
sion. Currently it is unclear exactly where and when these
iPSC-associated SNVs arose. At least two possibilities can be
envisioned, which are not mutually exclusive. First, these SNVs
are simply normal mitotic mutations during iPSC induction
(presumably from a single cell) and/or subsequent expansion
before WGS. Second, a founder somatic cell from adult tissues
that has been reprogrammed to a clonal iPSC line may already
contain most if not all of these SNVs. Both are related to the
fact that somatic DNA mutations occur along mitotic cell divi-
sions both in vivo and in vitro.
Estimation of mutational rates in somatic cells varies signifi-
cantly by previous methods, which typically depend on the
expression of a functional gene (Araten et al., 2005; Lynch,
2010). Recent WGS analysis provides a more definitive and
selection-independent method to measure mutational frequen-
cies in both exonic and nonexonic regions in normal primary cells
as well as in cultured human cell lines (Kinde et al., 2011). Based
on these studies, we used the estimation of 3 to 30mutations per
haploid genome per mitotic division for somatic cells in the
following discussion. Formation of a sizable iPSC colony
(1,000 cells), presumably from a single somatic cell during
our episome-mediated reprogramming, takes 2 weeks and
requires 10 cell divisions. Subsequently we expanded iPSCs
for 15–25 passages, with an estimated >3 cell divisions per
passage, before sequencing. Therefore, it is conceivable that
some of the SNVs we observed in iPSCs may have arisen during
iPSC induction and subsequent expansion (the first possibility).
However, the SNVs found in iPSCs could have also been in-
herited from a given somatic cell that was reprogrammed
successfully (the second possibility). Considering that a typical
human somatic cell is derived from a fertilized egg after 46–47
cell divisions during embryonic, fetal, and postnatal develop-
ment, each somatic cell is expected to harbor 138–1,410 spon-
taneous mutations that differ from those in another cell in the
population. Because we set the algorithms to consider
a sequence change to be real if it is present in at least 10% of
the reads (both nuclear and mitochondrial DNA sequences),342 Cell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc.the detected SNVs should have been either pre-existing in a
founder somatic cell that was reprogrammed or acquired within
3–4 cell divisions after iPSC induction (when a single colony
was formed and picked). Otherwise, a later acquired mutation
cannot be present inR10% of the derived iPSCs unless it offers
a growth advantage in subsequent expansions and is preferen-
tially retained. In our present study, we found 1,058–1,808
sequence changes, mostly SNVs, per genome in the 3 iPSC
lines, which are within the expected ranges for a normal human
somatic cell in adults. The present study therefore corroborates
with a recent report that at least 50% of the SNVs or small
sequence changes found by exome sequencing of the examined
iPSC lines can be found in parental somatic cell populations
(Gore et al., 2011). The somatic origin of SNVs was also sup-
ported by our data of the mitochondrial DNA sequencing. In
the BC1 iPSC line where a single SNV was found in the noncod-
ing region, the variant sequence was found in all the reads
although a cell contains hundreds or thousands of mitochondrial
DNA genomes. Overall, our WGS data indicate that reprogram-
ming of iPSCs by episomal vectors is not inherently mutagenic.
We predict that the level of SNVs found in the iPSC lines is prob-
ably of the samemagnitude as those found in other adult somatic
(stem) cells after extended proliferation.
It is possible that somatic cells harboring sequence variations
that favor iPSC induction and expansion could have been
selected for iPSC reprogramming. Those iPSCs with additional
sequence variants generated during early passages that favor
iPSC growth may be enriched during clonal expansion. Although
we cannot rule out these possibilities completely, they do not
seem to be likely for the three iPSC lines studied here, based
on the following two reasons. First, bioinformatic analysis of
the genes harboring nonsynonymous, premature termination
and deletion variants did not reveal a recurrent pattern of
mutating a single common gene or signal pathway, similar to
the recent exome sequencing study (Gore et al., 2011). None
of the SNVs we found (in exons and other regions) are shared
among the three iPSC lines sequenced here or with those found
in the previous exome sequencing study. Second, the ratios of
nonsynonymous:synonymous substitutions (NS:S), which was
traditionally applied to germline mutations that have evolved
over a long period of evolutionary time, are 1, 0.5, and 1.4 for
each iPSC line, respectively (Table 2), or 1.1 (13:12) as a group.
These ratios are lower than 2.6 as reported recently for fibro-
blast-derived iPSC lines by exome sequencing (Gore et al.,
2011), whereas the three cited cancer WGS studies reported
NS:S ratios of 0.97, 1.78, and 2.64, respectively (Lee et al.,
2010; Pleasance et al., 2010; Ding et al., 2010). Although the
significance or relevance of using NS:S ratios in analyzing
somatic mutations in cancers or iPSCs remains to be deter-
mined, the observed NS:S ratio (1:1) of SNVs in our integra-
tion-free three iPSC lines derived by episomal vectors did not
suggest that they bear such a characteristic if it is proven to be
a cancer cell signature. Notably, the SNVs found in all the iPSCs
sequenced by us and Gore et al. (2011) did not cluster in few
genes or a group of genes encoding proteins related to
a common functional pathway, such as recurrent mutations in
TP53, RAS, RAF, PTEN, and PIK3CA genes found in multiple
cancer samples sequenced (Lee et al., 2010; Pleasance et al.,
2010; Ding et al., 2010). The analysis of SNV patterns such as
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Whole-Genome DNA Sequence Variations in Human iPSCsNS:S ratios in known functional regions further supports the
notion that iPSC derivation by an improved method is not inher-
ently tumorigenic or mutagenic. Future experimental studies,
however, are still needed to determine the functional importance
of the observed DNA sequence variations in iPSCs, for their
growth and differentiation to various cell lineages, and whether
these variations have any adverse consequences.
The robust, unbiased, and increasingly affordable WGS tech-
nology for analyzing genome integrity of iPSCs and other cell
types is not without limitations. Because read lengths and library
fragment lengths span only a few hundred bases and read
depths are randomly distributed, accurately detecting CNVs
and other structural rearrangements (such as inversions, translo-
cations, transposon insertions, and others associated with
repetitive sequences) by the current WGS technology remains
difficult. Because WGS analysis alone cannot fully rule out the
existence of CNV changes between iPSCs and their parental
somatic cells, we also detected CNVs with the 2.5M SNP array.
The data from both SNP array and WGS technologies were
analyzed with multiple algorithms. We did not observe CNV
changes (up to 51 passages) in these three iPSC lines derived
by episomal vectors, although others found CNV alterations in
a fraction of iPSCs derived from fibroblasts by integrating viral
vectors (Hussein et al., 2011; Laurent et al., 2011; Martins-Taylor
et al., 2011). It is unclear what factors contribute to the discrep-
ancy. The absence of detectable CNVs in our iPSC lines could be
due to the fact that different types of parental somatic cells
and/or reprogramming vectors were used. We used human
CD34+ cells and MSCs after short cultures and episomal vectors
for generating integration-free iPSCs, whereas the previously re-
ported iPSCs were derived from extensively cultured fibroblasts
with integrating viral vectors.
In summary, we have conducted a deep whole-genome
sequencing of three independently derived and functionally
characterized iPSC lines from a single donor to comprehensively
document the number and type of sequence variations in these
iPSC lines. Unbiased whole-genome DNA sequencing is a defin-
itiveway to identify vector DNA integration andmutations in iPSC
lines. The data presented in this report suggest that the genome
of an iPSC line derived by episomal vectors could be largely
intact: less than one SNV per megabase of DNAwhen compared
to the parental somatic cells, despite clonal selection and many
cycles of mitotic cell divisions during iPSC reprogramming and
subsequent expansion. The existence of these DNA sequence
variations in thousands as compared to the starting somatic
cell population, however, suggests that each established iPSC
line needs to be characterized thoroughly at the genomic DNA
level before it is used for comprehensive functional studies and
clinical applications.EXPERIMENTAL PROCEDURES
Anonymous Adult Human Somatic Cells Used for Reprogramming
Human primary mononuclear cells (MNCs) obtained from bone marrow and
blood of anonymous donors were collected and processed at AllCells, LLC
(Emeryville, CA). The consent form signed by the healthy adult male donor
coded as BM2426 is available upon request. The practice of obtaining bone
marrow aspirates and blood from adult donors was approved by Institutional
Review Board (IRB) at AllCells. Use of anonymous human samples for labora-
tory research including iPSC derivation was approved by IRB and the Institu-Ctional Stem Cell Research Oversight (ISCRO) committee at Johns Hopkins
University.
HumanMNCs from themarrow donor BM2426were isolatedwith a standard
gradient protocol by Ficoll-Paque Plus (p = 1.077). The humanMNCs express-
ing a high level of the CD34 surface marker (CD34+) were purified with the
MACS magnet system and CD34 isolation beads (Miltenyi, Auburn, CA). The
CD34-depleted (CD34) MNCs were used to establish marrow stromal cells
(also called mesenchymal stem cells or MSCs) by a standard protocol (Cheng
et al., 2003; Mali et al., 2010). In brief, total unfractionated CD34 MNCs were
first cultured for 2 days in DMEM (low glucose) plus 10% FBS in standard
adherent tissue culture flasks. After discarding hematopoietic cells that re-
mained in suspension at day 2, MSCs as adherent cells were then selectively
expanded until subconfluence before harvest by trypsin digestion. The result-
ing adherent cells (called passage zero or p0) were replated under the same
condition, expanded, and harvested at subconfluence as p1 (15 days in
culture). The cultured p1 MSCs were used for cell reprogramming as well as
DNA analysis as described below.
Human iPSC Lines Derived from Adult Marrow CD34+ Cells
and MSCs from BM2426
The BC1 iPSC line was derived from the BM2426 CD34+ cells (after in
a hematopoietic culture for 4 days) by a single episomal vector pEB-C5 as
previously described (Chou et al., 2011). The BCT1 iPSC line was derived
from the same cultured marrow CD34+ cells as BC1, except that the second
episomal vector pEB-Tg expressing SV40-LT transiently was also used in
addition to pEB-C5. For reprogramming MSCs, 0.5 3 106 cells were nucle-
ofected by up to 5 mg DNA plasmid with Lonza/Amaxa’s recommended MSC
solution and electroporation parameter as we previously used in the DNA
transposon vector study (Mali et al., 2010). In this study, we used episomal
vectors (such as combination #6) for reprogramming MSCs as described
previously (Chou et al., 2011; Yu et al., 2009). Four days after transfection
by two or three plasmids, human embryonic stem cell medium was added
in the presence of sodium butyrate as we previously described (Mali et al.,
2010; Chou et al., 2011). The efficiency of iPSC derivation from adult
MSCs was 1 per 106 transfected MSCs even when three episomal vectors
were used. Among various clones we picked and expanded, two (E1 and E2)
were fully characterized by the functional assays such as pluripotency and
karyotyping. G-banded karyotyping was conducted by a certified cytogenet-
icist (Cheng et al., 2003; Mali et al., 2010). In brief, at least 20 metaphases
for each sample were counted and partially analyzed. At least 5 of the 20
spreads were fully analyzed in detail. Resolution of 300–450 bands was
obtained. This analysis rules out mosaicism of greater than 14% with 95%
confidence.
Whole-Genome Sequencing and Analysis
Whole-genome DNA libraries suitable for sequencing on Illumina’s se-
quencing platform were generated from 5 mg of genomic DNA with the
TruSeq Sample Prep Kit from Illumina. The DNA was sheared to approxi-
mately 450 bp with a Covaris E210. Size selection was achieved on a Pippin
Prep with 1.5% agarose cassettes (Sage Science). The libraries were
sequenced on HiSeq2000 DNA Sequencers (Illumina). Although samples of
S1 (BC1 iPSC) and S2 (CD34+ cells) were sequenced at BGI with 90 bp
paired-end reads, samples S3 (MSC), S4 (MSC-derived E1 iPSC), S5
(CD34+ cells again), and S6 (BCT1 iPSC) were sequenced at NISC with
101 bp paired-end reads (Figure 1). Details of WGS analyses are provided
in Supplemental Information.
Genomic DNA PCR and Sanger Sequencing
Sequence variants found by whole-genome sequencing were confirmed by
PCR-Sanger sequencing with an ABI 3100 Genetic Analyzer (Applied Bio-
systems). In brief, 20 ng genomic DNA samples from iPSC lines, their parental
cells and an unrelated control blood sample were used for PCR reactions with
primers located about 100–200 bp at either side of the selected sequence
variants (Table S2). PCR reactions were cleaned with Exo-SAP-IT (Affymetrix)
and followed by sequencing reactions with BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems). The sequence data were analyzed with
Sequencher 4.10.1.ell Stem Cell 10, 337–344, March 2, 2012 ª2012 Elsevier Inc. 343
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Genotyping was performed with the HumanOmni2.5_Quad v1.0 DNA analysis
BeadChip kit (Illumina, Inc.) and 300 ng of genomic DNA per the Illumina ‘‘in-
finium assay’’ protocol (Gunderson et al., 2005). CNVs were detected with
the Illumina GenomeStudio ‘‘in-house’’ algorithm, cnvPartition v3.1.6,
PennCNV, and Nexus 5.1. Details of CNV analyses are provided as Supple-
mental Information.
ACCESSION NUMBERS
The raw SNP data from the HumanOmni2.5_Quad v1.0 array are deposited at
http://research.nhgri.nih.gov/. The three lists (A, B, and C) of all CNV calls we
analyzed by each of the three methods (PennCNV, cnvPartition, and Nexus)
are also available at the website.
The raw sequencing data reported in this study have been submitted to the
Sequence Read Archive (SRA) at NCBI (accession number SRA048525),
which can be accessed at http://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
doi:10.1016/j.stem.2012.01.005.
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